Remarkable Role of Chemotherapy in Selected ALK-Positive Non–Small-Cell Lung Cancer Before or After Targeted Therapy: Two Case Reports

2020 ◽  
pp. 1425-1428
Author(s):  
Kunal Gawri ◽  
Richa Dawar ◽  
Kayla Haines ◽  
Mohammad Jahanzeb
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Case Reports ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive

scholarly journals Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer

2017 ◽  
Vol 18 (1) ◽  
pp. 63-70 ◽  
Author(s):  
Misako Nagasaka ◽  
Shirish M. Gadgeel
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung

New Role of Tumor Mutation Burden as a Predictor to Chemo/Targeted Therapy in Advanced Non-Small Cell Lung Cancer

2019 ◽  
Author(s):  
Chen Lin ◽  
Xun Shi ◽  
Jun Zhao ◽  
Qiong He ◽  
Yang Shao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Mutation Burden ◽  
Mutation Burden

EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity

2012 ◽  
Vol 8 (8) ◽  
pp. 1015-1029 ◽  
Author(s):  
Elena Galvani ◽  
Godefridus J Peters ◽  
Elisa Giovannetti
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egf Receptor ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Experience of targeted therapy for ALK positive non-small cell lung cancer – a clinical case

2020 ◽  
pp. 181-186
Author(s):  
A. V. Sultanbaev ◽  
Sh. I. Musin ◽  
K. V. Menshikov ◽  
A. F. Nasretdinov ◽  
B. A. Ibragimov ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
High Efficiency ◽  
Small Cell ◽  
Smoking History ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Alk Positive

Lung cancer holds a leading position in the cancer mortality pattern worldwide. The emergence of knowledge about driver mutations heralded a new era in the targeted therapy for lung carcinomas. ALK translocation is identified in 5–7% of non-small cell lung cancer cases. ALK-positive lung adenocarcinomas are associated with specific clinical features, including no or light smoking history and younger age. Alectinib is a novel ALK inhibitor that has been granted a breakthrough therapy status by the FDA to accelerate approval as a second-line therapy after progression during crizotinib therapy.Here, the case of a patient with metastatic ALK-positive lung adenocarcinoma treated with alectinib has been discussed. Molecular genetic testing for driver mutations makes it possible to personalize approaches to anticancer drug therapy. At the same time, the custom-compounded targeted therapy is more often accompanied by significant objective responses and moderate symptoms of toxicity, which is relevant for patients in critical condition. The experience in using alectinib demonstrates the possibility of its long-term administration with high efficiency and a controlled safety profile.

Sign in / Sign up

Export Citation Format

Share Document